We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Review
Targeting synuclein-gamma to counteract drug resistance in cancer.
Expert Opinion on Therapeutic Targets 2008 January
BACKGROUND: Expression of synuclein-gamma (SNCG) protein is elevated in the advanced stages of many types of cancers, including ovarian, lung, liver, esophagus, colon, prostate and, in particular, breast. In breast carcinoma, SNCG is causatively linked to stimulated proliferation, metastasis and drug resistance.
OBJECTIVE: To establish SNCG as a potential therapeutic target and to discuss clinical use of SNCG inhibiting peptide.
METHODS: This review focuses on the plausible mechanisms of SNCG activity, SNCG mediated drug resistance and its inhibition.
RESULTS/CONCLUSION: Evidence based research shows that the aberrant expression of SNCG has a strong correlation with breast cancer progression and poor clinical outcome. A peptide based inhibitor counters activity of SNCG, which may be developed as an adjuvant therapy.
OBJECTIVE: To establish SNCG as a potential therapeutic target and to discuss clinical use of SNCG inhibiting peptide.
METHODS: This review focuses on the plausible mechanisms of SNCG activity, SNCG mediated drug resistance and its inhibition.
RESULTS/CONCLUSION: Evidence based research shows that the aberrant expression of SNCG has a strong correlation with breast cancer progression and poor clinical outcome. A peptide based inhibitor counters activity of SNCG, which may be developed as an adjuvant therapy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app